Economic evaluation of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Mexico

Economic evaluation of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Mexico

Objectives: To undertake an economic evaluation of denosumab in comparison with a mixed scenario consisted of zoledronic acid or no treatment if there is a contraindication to this agent due to severe renal impairment (Mix ZA/No tx) in patients with multiple myeloma (MM). Methods: The analysis adopt...

Full description

Bibliographic Details
Main Authors:	Fernando Carlos-Rivera, Jorge A. Guzmán-Caniupan, Adolfo Hernández-Garduño, Mónica Alva-Esqueda, Therese Aubry-de Maraumont, Luis M. Camacho-Cordero
Format:	Article
Language:	English
Published:	Permanyer 2022-04-01
Series:	Gaceta Mexicana de Oncología
Subjects:	Economic evaluation. Cost-effectiveness. Denosumab. Zoledronic acid. Skeletal-related events. Multiple myeloma.
Online Access:	https://www.gamo-smeo.com/frame_esp.php?id=282

Similar Items

Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years
by: Chi Zhang, et al.
Published: (2018-11-01)

The importance of retaining physical functions to prevent skeletal‐related events in multiple myeloma patients with bone disease
by: Hirokazu Miki, et al.
Published: (2022-05-01)

EvaluaciÃ³n econÃ³mica de denosumab en pacientes con tumores sÃ³lidos con metÃ¡stasis Ã³seas en el IMSS
by: Fernando Carlos-Rivera, et al.
Published: (2023-04-01)

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
by: Zachary S. Bernstein, et al.
Published: (2022-07-01)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
by: Si Su, et al.
Published: (2023-11-01)

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials
by: Lianghai Jiang, et al.
Published: (2021-06-01)

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
by: Benoit Cadieux, et al.
Published: (2022-04-01)

Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ
by: Ilaria Roato, et al.
Published: (2023-10-01)

Targeted Treatments of Bone Metastases in Patients with Lung Cancer
by: Vera eHirsh
Published: (2014-06-01)

Comparison of the Efficacy of Zoledronate and Denosumab in Patients with Acute Osteoporotic Vertebral Compression Fractures: A Randomized Controlled Trial
by: Seong Son, et al.
Published: (2024-04-01)

65 Yaş Üstü Osteoporoz Hastalarında Denosumab ve Zoledronik Asit’in Yan Etkilerinin Karşılaştırılması
by: Rabia Bağ Soytaş, et al.
Published: (2021-06-01)

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
by: Jiaji Yue, et al.
Published: (2022-08-01)

Denosumab induction and Zoledronic acid maintenance therapy for recurrent unresectable giant cell tumour of the distal tibia: A case report with sustained tumour control after drug withdrawal
by: Gennady N. Machak, et al.
Published: (2024-04-01)

Potential protective effect of zoledronic acid when switching from long-term therapy of osteoporosis with denosumab
by: O. V. Yakushevskaya
Published: (2021-01-01)

Giant cell tumour of bone in os sacrum of a prepubertal girl – Surgical and medical treatment with zoledronate and denosumab
by: Signe Sparre Beck-Nielsen, et al.
Published: (2023-06-01)

The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia
by: Nutrisia Aquariushinta Sayuti, et al.
Published: (2020-09-01)

Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned
by: Christian Thomas, et al.
Published: (2016-08-01)

Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study
by: Kohei Mizuta, et al.
Published: (2023-10-01)

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials
by: Junjie Lu, et al.
Published: (2023-02-01)

Multiple Myeloma Associated Bone Disease
by: Stine Rasch, et al.
Published: (2020-07-01)

Pathogenesis and Treatment of Myeloma-Related Bone Disease
by: Yuh-Ching Gau, et al.
Published: (2022-03-01)

Treatment of bone complications in multiple myeloma patients
by: V. V. Ptushkin
Published: (2022-11-01)

Multiple myeloma: imaging evaluation of skeletal disease
by: Carlton Sexton, et al.
Published: (2013-07-01)

Osteoclast Fusion: Physiological Regulation of Multinucleation through Heterogeneity—Potential Implications for Drug Sensitivity
by: Kent Søe
Published: (2020-10-01)

The real-world adherence of the first-line anti-osteoporosis medications in Taiwan: Visualize the gap between reality and expectations
by: Chia-Che Lee, et al.
Published: (2023-01-01)

Atypical tibial fracture in breast cancer patient with bone metastasis receiving denosumab therapy: a case report and review of the literature
by: Yohei Yanagisawa, et al.
Published: (2023-06-01)

Differences in interactions with the bone microenvironment between solid tumors and multiple myeloma: pathogenetic aspects. Possibilities and effectiveness of osteomodifying agents in multiple myeloma
by: A. V. Snegovoy, et al.
Published: (2021-04-01)

Identification and in-vitro analysis of potential proteasome inhibitors targeting PSMβ5 for multiple myeloma
by: Rohitash Yadav, et al.
Published: (2023-01-01)

Management of Myeloma Bone Lesions
by: Jeng-Shiun Du, et al.
Published: (2021-03-01)

Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients
by: Nikolaos Kanellias, et al.
Published: (2022-05-01)

Augmentation of IFN-γ by bone marrow derived immune cells in the presence of severe suppression of IFN-γ in gingivae induced by zoledronic acid and denosumab in Hu-BLT mice model of ONJ
by: Kawaljit Kaur, et al.
Published: (2023-01-01)

Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology
by: Prasad Apsangikar, et al.
Published: (2022-04-01)

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
by: Megan M. Tu, et al.
Published: (2021-05-01)

Comparison of antiresorptive agents in the treatment of osteoporosis in older adults
by: Zeynel Abidin Öztürk, et al.
Published: (2022-09-01)

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies
by: Sonia Vallet, et al.
Published: (2018-10-01)

Anti-osteoporotic treatment and COVID-19 risk: is there an association?
by: N.V. Grygorieva, et al.
Published: (2022-06-01)

Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw
by: Winnie Zee Man Wat
Published: (2016-10-01)

Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study
by: Ji-Yeon Kang, et al.
Published: (2023-06-01)

Long-term consequences of osteoporosis therapy with denosumab
by: Francisco Bandeira, et al.
Published: (2022-12-01)

Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling
by: Lei Shangguan, et al.
Published: (2024-12-01)